BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/15/2019 10:34:38 AM | Browse: 8 | Download: 22
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 45968
Country of Manuscript Source Japan
Received
2019-01-30 02:52
Peer-Review Started
2019-01-30 22:08
To Make the First Decision
2019-03-18 06:32
Return for Revision
2019-03-22 01:35
Revised
2019-03-28 08:36
Second Decision
2019-04-04 10:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-04-08 21:36
Articles in Press
2019-04-08 21:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-05-14 02:21
Publish the Manuscript Online
2019-05-15 10:34
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript type Observational Study
Article Title ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Hiroaki Takaya, Tadashi Namisaki, Naotaka Shimozato, Kosuke Kaji, Mitsuteru Kitade, Kei Moriya, Shinya Sato, Hideto Kawaratani, Takemi Akahane, Masanori Matsumoto and Hitoshi Yoshiji
ORCID
Author(s) ORCID Number
Hiroaki Takaya http://orcid.org/0000-0002-4990-7573
Tadashi Namisaki http://orcid.org/0000-0002-3158-5318
Naotaka Shimozato http://orcid.org/0000-0002-7558-4165
Kosuke Kaji http://orcid.org/0000-0002-1822-6759
Mitsuteru Kitade http://orcid.org/0000-0001-7592-7589
Kei Moriya http://orcid.org/0000-0002-2878-8296
Shinya Sato http://orcid.org/0000-0003-3049-3443
Hideto Kawaratani http://orcid.org/0000-0002-4361-0592
Takemi Akahane http://orcid.org/0000-0002-6675-0475
Masanori Matsumoto http://orcid.org/0000-0002-7243-3126
Hitoshi Yoshiji http://orcid.org/0000-0002-5243-8544
Funding Agency and Grant Number
Correspondence To Hiroaki Takaya, MD, PhD, Assistant Professor, Doctor, Third Department of Internal Medicine, Nara Medical University, 840 Shijo-cho, Kashihara 6348522, Japan. htky@naramed-u.ac.jp
Keywords ADAMTS13; Von Willebrand factor; Biomarkers; Hepatocellular carcinoma; Sorafenib
Core Tip There is an urgent clinical need to prediction of sorafenib response and prognosis in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment due to the potentially serious side effects of sorafenib in these patients. Multivariate analysis showed that the von Willebrand factor (VWF) antigen (VWF:Ag)/a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity (ADAMTS13:AC) ratio was the only predictive factor for sorafenib response and ADAMTS13:AC was the only prognostic factor in patients with HCC receiving sorafenib treatment. The VWF:Ag/ADAMTS13:AC ratio and ADAMTS13:AC are potentially useful biomarkers for sorafenib response and prognosis, respectively, in patients with HCC receiving sorafenib treatment.
Publish Date 2019-05-15 10:34
Citation Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(5): 424-435
Url https://www.wjgnet.com/1948-5204/full/v11/i5/424.htm
DOI https://dx.doi.org/10.4251/wjgo.v11.i5.424
Full Article (PDF) WJGO-11-424.pdf
Full Article (Word) WJGO-11-424.docx
Manuscript File 45968-Review.docx
Answering Reviewers 45968-Answering reviewers.pdf
Audio Core Tip 45968-Audio core tip.m4a
Biostatistics Review Certificate 45968-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 45968-Conflict-of-interest statement.pdf
Copyright License Agreement 45968-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 45968-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 45968-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 45968-Language certificate.pdf
Peer-review Report 45968-Peer-review(s).pdf
Scientific Misconduct Check 45968-Scientific misconduct check.pdf
Scientific Editor Work List 45968-Scientific editor work list.pdf